ReviewMicromachines2026
Microfluidics-Assisted Three-Dimensional Confinement of Cholesteric Liquid Crystals for Sensing Applications.
Review in Micromachines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Luminescent Nanocomposites of Liquid Crystals and Carbon Dots in Microfluidic Channels: Effects of Walls, Dynamics, and Bioactive Additive.Nanomaterials (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
As a class of self-organized soft matter systems merging fluidic mobility with long-range molecular order, cholesteric liquid crystals (CLCs) possess immense potential for the development of high-sensitivity, visually tractable flexible sensors. Leveraging their unique helical superstructures and stimuli-responsive photonic bandgaps, CLCs can transduce subtle physical or chemical perturbations into discernible optical signatures, such as Bragg reflection shifts or mesomorphic textural transitions. Nonetheless, the intrinsic fluidity of CLCs often compromises their structural integrity, while conventional one-dimensional (1D) or two-dimensional (2D) confinement geometries exhibit pronounced angular dependence, significantly constraining their detection precision in complex environments. Recently, microfluidic technology has emerged as a pivotal paradigm for achieving sophisticated three-dimensional (3D) spatial confinement of CLCs through the precise manipulation of microscale fluid volumes. This review systematically delineates recent advancements in microfluidics-enabled CLC sensors. Initially, the fundamental self-assembly principles and optical properties of CLCs are introduced, emphasizing the unique advantages of 3D spherical confinement in mitigating angular sensitivity and intensifying interfacial interactions. Subsequently, the primary sensing mechanisms are bifurcated into bulk-driven sensing via pitch modulation and interface-driven sensing via topological configuration transitions. We then detail the microfluidic-based fabrication strategies and engineering protocols for diverse 3D architectures, including monodisperse/multiphase droplets, microcapsules, shells, and Janus structures. Building upon these structural frameworks, current sensing applications in physical (temperature, strain/stress), chemical (volatile organic compounds, ions, pH), and biological (biomarkers, pathogens) detection are evaluated. Lastly, in light of persistent challenges, such as intricate signal interpretation and limited robustness in complex matrices, we propose future research trajectories, encompassing the co-optimization of geometric parameters (size and curvature), artificial intelligence-enhanced automated diagnostics, and multi-field-coupled intelligent integration. This work seeks to provide a comprehensive roadmap for the design of next-generation, high-performance, and portable liquid-state photonic sensing platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.